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A B S T R A C T
Current clinical antidiabetic drugs, like rosiglitazone 1, have been implicated in some serious side effects like
edema, weight gain, and heart failure, making it necessary to find alternative agents. Partial agonists of perox-
isome-proliferator activated receptor-gamma (PPARγ) were determined to possess improved insulin sensitivity
without undeseirable side-effects when compared to full agonists of PPARγ, like rosiglitazone 1. The traditional
Chinese medicine (TCM) plants, Goji (Lycium barbarum and Lycium chinense) are widely used for treating symp-
toms related to various diseases including diabetes and hypertension. Twenty-seven reported compounds from
Goji were docked into both partial- and full-agonist binding sites of PPARγ. Amongst the docked compounds,
phenylethylamide-based phytochemicals (5–9) (termed as tyramine-derivatives, TDs) were found to possess
good docking scores and binding poses with favorable interactions. Synthesis of 24 TDs, including three
naturally occuring amides (6, 8, 9) were synthesized and tested for PPARγ gene induction with cell-based
assay. Three compounds showed similar or higher fold induction than the positive control, rosiglitazone.
Among these three active TDs, trans-N-feruloyloctopamine (9) and tyramine derivatives-enriched extract (TEE)
(21%) of the root bark of L. chinense were further studied in vivo using db/db mice. However, both TEE as well as 9
did not show significant antidiabetic properties in db/db mice. In vivo results suggest that the proposed
antidiabetic property of Lycium species may not be due to tyramine derivatives alone. Further studies of
tyramine derivatives or enriched extract(s) for other bioactivities like hypocholesterolemic activities, and
studies of novel isolated compounds from Goji will enable a more complete understanding of their bioactivities.
1. Introduction
Type 2 diabetes mellitus (T2DM), a disorder resulting from insulin
resistance and impaired pancreatic beta cell function, has reached
epidemic proportion and is responsible for 1.5 to 5.5 million deaths per
year in 2012 and 2013, worldwide. As per World Health Organization
(WHO) statistics, T2DM accounts for about 90% of the total diabetic
populations of 382 million, which was 8.3% of the total adult population
in 2012–2013 [1]. According to the American Diabetes Association, there
are approximately 1.5 million new cases of diabetes each year and, if the
current trend continues, these numbers are projected to increase to a
third of the population by 2050 [2]. Alarmingly, patients with impaired
glucose and lipid metabolisms have increased risk of developing com-
plications such as dyslipidemia, hypertension, and other adverse car-
diovascular effects. Current antidiabetic drugs include: metformin
(biguanide), which reduces gluconeogenesis; sulfonyl ureas (gliburide,
glipizide, glimpiride), which are insulin secretagogues; competitive
α-glucosidase inhibitors (acarbose, miglitilol); and thiazolidinediones
(TZDs) which include rosiglitazone 1 (Avandia®) and pioglitazone
(Actos®) are effective in improving insulin and glucose parameters and
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increase whole-body insulin sensitivity [3]. TZDs decrease hepatic
glucose production and prolong pancreatic β-cell function by preventing
apoptosis of β-cells [3]. TZDs exert their action by acting as agonists to
nuclear receptor peroxisome proliferator-activated receptor subtype
gamma (PPARγ). The structure of apo-PPARγ site along with
co-activating factor SRC-1 was determined (PDB: 2PRG) (Supplementary
information, SI Figure A.1) [4]. Depending on their interaction with the
key residues in the ligand binding domain of PPARγ, there are two
binding modes of PPARγ agonists: full-agonist and partial-agonist (Sup-
plementary information, SI Figure A.2). Although TZDs are useful in
treating T2DM, adverse effects like weight-gain, edema, and anemia are
often observed with full agonists like rosiglitazone 1 and the treated
populations have increased risk for cardiovascular events and bone
fracture [5]. The other adverse side effects associated with rosiglitazone
include congestive heart failure, volume-overload, systemic edema due
to fluid retention and subsequent increase in intravascular volume [3].
The partial agonists like cercosporamide [6, 7, 8, 9, 10] (Fig. 1) improve
insulin sensitivity without causing undesirable side-effects associated
with full agonists like TZDs [11,12] and interact differently at the PPARγ
binding site. In addition to antidiabetic properties, PPARγ agonists have
been shown to exhibit pleiotropic beneficial effects in addition to its
blood glucose-lowering effects. These include effects on vasculature,
lowering of blood pressure, preventing the progression of atherosclerosis,
and reno-protective effects by reducing the urinary albumin in both
human and animals [13].
Several natural products have been reported to possess PPARγ ac-
tivities with reduced side-effects compared to TZDs [8,14, 15, 16, 17, 18]
and bind with PPARγ binding pocket in a manner different from full
agonists. We hypothesize that small molecules isolated from traditionally
used plants could possess PPARγ activities with reduced side-effects
compared to TZDs. Our objectives were to apply computational
methods for the identification of potential PPARγ modulators, validate
with cell-based methods and confirm the preliminary results with animal
models. Plants such as Lycium barbarum and L. chinense, also known as gou
qi zi or Goji, wolfberry, Chinese wolfberry or matrimony wine, have been
widely used in Asian countries for the treatment of a number of
symptoms related to [12, 19] diabetes, inflammation and as a tonic for
well-being. The phytochemicals reported from Goji were claimed to
exhibit antioxidant, antitumor, immunomodulatory, cardioprotective,
antidiabetic and neuroprotective activities [19, 20, 21, 22, 23, 24, 25, 26,
27, 28, 29, 30, 31, 32]. The dried root bark of L. barbarum, has been
shown to produce long-term hypoglycemic effects and reduced body
weight in diabetic mice [23]. Methanolic extracts made from the root
bark of L. chinense were claimed to possess hypocholesterolemic and
antioxidant effects [33]. In order to identify novel PPARγ modulators
with reduced side-effects, for the treatment of T2DM, we carried out this
study in four parts.
Stage 1: Docking studies to identify the reported phytochemicals of
Goji which occupy the same chemical space as that of the known agonist
and partial agonist binding pockets of PPARγ.
Stage 2: Synthesis of naturally occurring phenethylamides and related
analogs.
Stage 3: In vitro screening of tyramine-like compounds for PPARγ/
PPARα agonistic activity.
Stage 4: In vivo study of a small molecule and phenethylamides-
enriched extract for antidiabetic activity, with db/db mice.
2. Results and discussion
Twenty-seven reported- (at the time of our study) phytochemicals
isolated from various parts of Goji (L. barbarum and L. chinense), were
selected for the docking studies (Fig. 2). These include terpenes,
tyramine-based phenethylamides, amide derivatives, N-methyl calyste-
gines, pyrrole analogs, cyclic peptides and glycosides.
2.1. In silico molecular docking
Both the partial- and full- agonist binding sites of PPARγwere utilized
for docking studies. Partial- and full- agonists possess dissimilar binding
modes by possessing variable ligand-residue interactions. While full ag-
onists (rosiglitazone 1, PDB: 2PRG) show good hydrogen bonding in-
teractions with His343 on helix 4, His449 on helix 10, and Tyr473 on
Fig. 1. Types of PPARγ ligands. a) Full agonists: Rosiglitazone 1 and Farglitazar 2; b) Partial agonists: Cercosporamide-derivative 3 and L-764406 4.
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helix 12, partial agonists (Cercosporamide-derivative 3, PDB: 3LMP) do
not show any interactions with these residues. However, partial agonists
occupy the binding site in the region between helix 3 and the β-sheet
(Supplementary information, SI Figure A.2).
Using the X-ray crystal structures of both full agonist rosiglitazone 1
(PDB ID: 2PRG) and partial agonist, cercosporamide-derivative 3 (PDB
ID: 3LMP) [12], docking was performed on the ligand binding domain of
PPARγ using the twenty seven reported compounds isolated from various
parts of both L. barbarum and L. chinense. Grids were generated around
the native ligand using the Glide SP module (Schr€odinger, LLC) with 12 Å
radii generated with different hydrogen bonding constraints for full
(2PRG) and partial agonist (3LMP) crystal structures. For the full agonist
crystal structure, 2PRG, three hydrogen-bonding constraints (His343 on
helix 4, His449 on helix 10, and Tyr473 on helix 12) were applied, and in
the partial agonist crystal structure, 3LMP, no constraints were applied.
The output of docking in both partial- (3LMP) and full- agonist (2PRG)
Fig. 2. List of the compounds used for docking studies in PPARγ crystal structures PDB ID: 2PRG (Rosiglitazone 1), 3LMP (Cercosporamide-derivative 3). a) Amide
derivatives, b) Tyramine derivatives, c) Pyrrole derivatives, d) N-methyl calystegines, e) Terpene derivatives, f) Cyclopeptide (Licumin D), g) other Goji compounds
and h) known PPAR agents.
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binding sites were analyzed (Supplementary information, SI Tables 1 &
2) which revealed that several compounds possessed good binding poses
with favorable protein-ligand interactions. A study of the binding modes
and the docking scores revealed that five compounds possessed good
binding poses, comparable to the native ligands. These compounds
belonged to the cinnamomylphenethyl amide class (or phenyl-
ethylamides) termed tyramine derivatives TDs, hereafter for simplicity:
lyciumamide A 5, dihydro-N-caffeoyltyramine 6, cis-N-caffeoyltyramine
7, trans-N-caffeoyltyramine 8, trans-N-feruloyloctopamine 9 (Table 1).
TDs displayed binding poses similar to both full and partial agonists.
They showed good hydrogen bonding interactions with the residues on
the helix 3 and helix 12 (similar to the full agonist, rosiglitazone 1), as
well as occupying the region between helix 3 and β-sheet (mimicking the
binding pose of the partial agonist, cercosporamide-derivative 3), with
no apparent interaction with AF2 helix binding site (Figs. 3 and 4). This
suggested that TDs are capable of occupying both binding domains with
structural flexibility and may serve as a source of full and/or partial
agonists for PPARγ. Some of the TDs were previously studied and re-
ported to possess diverse biological activities including antitubercular
activity [34], inhibitors of bacterial efflux pump, melanin synthesis [35],
melanocyte-tyrosinase [36] and antifungal activities [37]. However,
their antidiabetic potentials including modulation of PPARs were not
reported. Recently, other types of tyramine derivatives were found to
possess α-glucosidase inhibitory activity [38].
2.2. Synthesis of tyramine derivatives (TDs)
To test the validity of in silico results, twenty-four tyramine analogs
(TDs) including three natural constituents of L. chinense (6, 8, 9) were
synthesized via simple peptide coupling conditions [39]. Four readily
Table 1
Docking scores of the five tyramine-based secondary metabolites in full agonist and partial agonist binding sites of PPARγ.
Compound Structure Glide Docking Score
2PRG (Agonist) 3LMP (Partial agonist)
Rosiglitazone (1) -11.68 (native ligand) -9.10
Cercosporamide-derivative (3) No docking result obtained -10.11 (native ligand)
Lyciumamide A (5) -8.36 -7.47
Dihydro-N-caffeoyltyramine (6) -8.82 -8.10
cis-N-caffeoyltyramine (7) -5.70 -6.26
trans-N-caffeoyltyramine (8) -7.50 -6.16
trans-N-feruloyloctopamine (9) -7.31 -8.11
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available cinnamic acids (10 to 13) were coupled with three readily
available tyramines (14 to 16) in the presence of triethylamine and
PyBOP [(benzotriazole-1-yloxy) tripyrrolidino-phosphoniumhexa-
fluorophosphate] as an activator to produce twelve TDs 8, 9, 17–26
which were further hydrogenated to their corresponding saturated ana-
logs 6, 27–37 (Scheme 1). All the 24 TDs (6, 8, 9, 17–37) were screened
with luciferase assays for agonistic activities towards both PPAR isoforms
(Section 2.4).
Fig. 3. a) Docked poses of the five tyramine-based secondary metabolites in PPARγ crystal structure with rosiglitazone 1, PDB: 2PRG. Tyramine derivatives- 5
(Brown), 6 (Blue), 7 (dark green), 8 (wheat), 9 (light green), Rosiglitazone 1 (yellow); key interacting residues in pink. b) Ligand-interaction diagram of 6 with key
amino acid residues of PPARγ (PDB: 2PRG).
Fig. 4. a) Docked poses of the five tyramine-based secondary metabolites in PPARγ crystal structure with cercosporamide-derivative, PDB: 3LMP; 5 (dark blue), 6
(brown), 7 (light blue), 8 (black), 9 (light green), 3LMP-ligand 3(green); key interacting residues in pink. b) Ligand-interaction diagram of 6 with key amino acid
residues of PPARγ (PDB: 3LMP).
Scheme 1. Synthesis of twenty-four tyramine derivatives. Reagents and conditions: a. PyBOP, TEA, DMF: DCM (1:1 v/v), 0 C, 12h (57–83%); b. H2 (1 atm) Pd/C,
MeOH, 12h (49–90%).
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2.3. Tyramine-enriched extract (TEE)
Four phenolic amides were previously reported to be isolated from
the root barks of L. chinense including dihydro-N-caffeoyl tyramine 6 (106
mg, 0.01325%), cis-N-caffeoyl tyramine 7 (9.2 mg, 0.00115%), trans-N-
caffeoyl tyramine 8 (14.8 mg, 0.00185), and trans-N-feruloyloctopamine
9 (19.6 mg, 0.00245%) [37, 40]. In order to study and compare the
antidiabetic properties of newly prepared TDs along with extract, an
enriched methanolic extract of the root bark of L. chinense (TEE) con-
taining 21% (calculated amount based on the literature values) TDs was
prepared to study in db/db mice.
2.4. In vitro PPAR luciferase assay
All the twenty-four synthesized tyramine derivatives were screened
for in vitro activity using PPARγ, PPARα luciferase assays [41]. These
compounds were screened for their selectivity towards PPARγ over
PPARα at three different concentrations of 30, 10 and 3 μM, along with
the known ligands rosiglitazone 1 (PPARγ agonist) and ciprofibrate
(PPARα agonist). PPARγ and PPARα agonistic activities of the com-
pounds were measured in terms of fold induction in luciferase expression
compared to the DMSO control, with a two-fold induction meaning a
100% increase. Among the twenty-four compounds, three compounds 9,
17 and 24 showed a considerable increase in PPARγ activity with a fold
induction of 2.0, 2.1 and 1.5 at 30 μM, respectively. Under the similar
experimental condition, rosiglitazone 1 showed an induction of 3.1 folds
(Table 2). However, PPARα induction by the synthesized compounds was
found to be negligible, showing the selective nature of these compounds
towards PPARγ. Based on these results, 9 was selected for further studies
with animal models.
2.5. In vivo testing in mice
Compound 9 and TEE (with ~21% tyramine derivatives) were tested
in vivo using diabetic db/db mice. The dosage of TEE was established on
the basis of the concentrations of tyramine-like compounds in the
enriched extract. Several parameters were measured including body
weight, food intake, glucose tolerance, metabolic data, body composi-
tion, blood pressure and heart rate for the mice treated with 9, and TEE
and the resulting data for the control vs treatment period at medium and
high doses were assessed. Rosiglitazone 1 is an FDA approved drug,
hence, it was not included in our animal studies.
2.5.1. Body weight, food intake and glucose tolerance measurements
Body weight and food intake of both high- and medium-dose db/db
mice groups were measured during the two weeks of control-period and
during the 18-day period of treatment with compound 9, TEE or vehicle.
In the high-dose groups, the mice treated with 9 showed a slight increase
in body weight, whereas, the group treated with TEE showed a slight
decrease in their body weight. The medium-dose groupmice treated with
TEE and 9 showed a slight decrease in body weight (Fig. 5). The food
intake of high-dose groups treated with 9 increased, while that of the
TEE-treated group decreased slightly. In the medium-dose group treated
with the TEE, the food intake decreased slightly, whereas the mice
treated with the drug remained the same (Fig. 5).
Glucose tolerance tests were performed in the mice treated with the
high- and medium-doses of the TEE and 9. In both medium- and high-
dose treated groups, no improvement was observed in baseline glucose or
in glucose tolerance in the mice treated with 9 or TEE. The data for
glucose tolerance in the medium and high dosage groups is shown in the
Fig. 6.
2.5.1.1. Metabolic data. Data related to respiratory quotient (RQ), oxy-
gen consumption (VO2), carbon dioxide production (VCO2), heat pro-
duction, and total movement were measured in both the medium- and
high-dose groups (Fig. 7a and b). In the medium-dose group treated with
9, the respiratory quotient, VO2,VCO2 decreased significantly, whereas,
the heat production decreased slightly and motor activity increased
slightly compared to the baseline. In the TEE treated medium-dose
group, all the metabolic parameters decreased slightly compared to the
baseline.
In the high-dose group mice treated with 9, the respiratory quotient
and total average movement decreased, while VO2, VCO2 and heat pro-
duction increased. In the TEE treated high-dose group, the respiratory
quotient decreased slightly, the total average motor activity increased
significantly, whereas, VO2, VCO2 remained the same and the heat pro-
duction decreased (Fig. 8a and b). However, these observed changes
appear to be not statistically significant.
2.5.1.2. EchoMRI body composition. Body composition was measured in
the medium-dose group using EchoMRI to assess lean and fat mass, free
and total water content (Fig. 9). In the drug-treated mice, lean mass, fat
mass and total water content almost remained the same as the baseline,
free-water content decreased by 42% in the first week, and it slightly
increased in the second week. In the TEE-treated group, the lean mass
remained the same, fat mass slightly increased by 5% in the first and
second weeks, and free-water content increased by 8% in the first week
and returned back to baseline in the second week.
2.5.1.3. Blood pressure and heart rate. Heart rate and blood pressure
were measured in the high-dose group after treatment with TEE and
compound 9. The heart rate of the mice (Fig. 10) slightly increased in
both 9 and TEE treated mice. The blood pressure in the high-dose group
of mice (Fig. 11) treated with the 9 slightly decreased, whereas, with the
TEE, the blood pressure slightly increased.
Based on the in vivo results, it can be inferred that the tyramine de-
rivative 9 and the enriched extract TEE, do not possess significant
antidiabetic activities. However, it should be noted that several novel
phytochemicals were later reported (and not included in these docking
studies) to be isolated form Goji and were reported to possess myriad of
bioactivities including activities against Alzheimer's disease with lyci-
barbarsermidines A–O, dicaffeoylspermidine derivatives [29].
Four new phenolic amides along with thirteen known phenolic am-
ides were identified recently from the stem of Lycium barbarum and were
evaluated against human glioma stem cell lines and two compounds
grossamide and 4-O-methylgrossamide were found to possess moderate
cytotoxicity [31].
In a randomized, double-blinded placebo-controlled trial, dietary
wolfberry extract was reported to modify oxidative stress by controlling
the expression of inflammatory mRNAs with slight but significant
decrease in erythrocyte superoxide dismutase activity and increase in
catalase activity [26]. This indicates that TDs could possibly be acting on
non-PPARγ dependent biological targets to possess antiinflammatory and
hypocholesterolemic activities. Further studies on these TDs, including
possible combination effects, will enable our understandings on their
overall bioactivity including multi-drug targets [42] to explain their
PPARγ-like anticancer and antiinflammatory activities.
Table 2
PPARγ activation by compounds 9, 17 & 24.
Compound Fold induction of PPAR gamma activity
30 μM 10 μM 3 μM
9 2.0  0.16 1.9  0.01 1.4  0.13
17 2.1  0.04 1.4  0.09 1.4  0.17
24 1.5  0.24 0.9  0.02 1.0  0.15
Rosiglitazone* 3.1  0.10 2.5  0.05 2.1  0.20
* Positive control.
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3. Conclusion
Preparations containing Goji, a traditional Chinese medicine (TCM)
plant, are widely used in the Eastern countries to treat various symptoms
including diabetes. To identify the active compounds, the reported
phytochemicals of Goji were selected and docked into the PPARγ ligand
binding domains of both full and partial agonists (2PRG and 3LMP,
respectively). Docking results revealed that five compounds belonging to
cinnamomylphenethyl amide class (5–9) (termed tyramine-derivatives)
(TDs), possess good binding poses and docking scores in both the par-
tial and full agonist binding domains. Hence, tyramine-derivatives were
selected for the synthesis followed by their further testing in cell-based as
well as animal models. A tyramine enriched extract TEE from the root
bark of L. chinense was prepared. Using a coupling reaction of phene-
thylamine with cinnamic acid-derivatives, followed by reduction,
twenty-four compounds belonging to the tyramine-derivatives were
synthesized, evaluated for PPARγ activity and selectivity using PPARγ-
and PPARα-luciferase bioassays. Among the twenty-four compounds,
three compounds (9, 17, and 24) possessed a good induction of PPARγ
compared to the positive control, rosiglitazone 1 and selectivity over
PPARα isoform.
To validate the in vitro data further, compound 9 and tyramine-
derivative enriched TEE were tested using in vivo diabetic db/db mice
to check their antidiabetic and metabolic properties. Although some
tyramine derivatives possessed good activities in vitro, the results of the in
vivo studies indicate no significant improvement in the biochemical pa-
rameters in db/db mice model for both 9 and tyramine-derivative
enriched Goji fraction.
In summary, though Goji has been reported and used for their anti-
diabetic properties as per TCM, our studies indicate that this antidiabetic
property may not be due to the TD-class of compounds either standalone
or in the enriched extract TEE, at the tested concentrations in vivo. It is
plausible that the phytochemicals of Goji including tyramine-analogs
might be working as antidiabetic compounds via different targets or
mechanisms other than activation of PPARγ or could possess other
relevant biological activities like hypocholesterolemic activities.
4. Experimental
4.1. Docking studies
Docking studies were performed using a commercial version of the
Schr€odinger software package [43] installed on a Windows desktop
computer with Intel® Core™ Quad CUP Q6600@2.40GHz 2.40 GHz
processor with a random access memory (RAM) of 4.00 GB and 32-bit
operating system. PyMol software (Schr€odinger, LLC) was utilized to
perform post docking visualization and analysis.
4.1.1. Protein preparation
Crystal structures of PPARγ with rosiglitazone 1, a full agonist (PDB:
2PRG) and cercosporamide-derivative 3, a partial agonist (PDB: 3LMP)
were prepared using the protein preparation wizard. Both the proteins
were preprocessed to assign bond orders, add hydrogen bonds, create
zero-order bonds to metals, create disulfide bonds, and delete water
molecules beyond 5 Å from the hetero groups. For 2PRG, the chains B and
C were deleted, whereas, for 3LMP, chain C was deleted. The H-bond
assignment was applied using sample water orientations, using PROPKA
pH 7.0. Water molecules with less than three hydrogen bonding distance
were removed from the protein. Restrained minimization was performed
using OPLS_2005, converged the heavy atoms to RMSD 0.3 Å.
4.1.2. Ligand preparation
Thirty compounds, including 27 from Goji and three PPARγ agonist
ligands like farglitzar, rosiglitazone 1 and cercosporamide-derivative 3
Fig. 5. Body weight (A, B) and food intake (C, D) by db/db mice in both high- and medium-dose group, treated with 9 and TEE (enriched with tyramine-
based amides).
C. Yalamanchili et al. Heliyon 6 (2020) e02782
7
were prepared using LipPrep module (Schr€odinger, LLC) in OPLS-2005
force field, ionized at pH 7.4  2, desalted and generated tautomers.
The specified chirality was retained to generate at most 32 per ligand.
This ligand preparation generated 81 ligands from the input of 30
compounds.
4.1.3. Glide grid generation and docking
Receptor grids were generated for the prepared proteins 2PRG and
3LMP using Glide (Schr€odinger, LLC). For 2PRG, three hydrogen bonding
constraints to His323, His449 and Tyr473 were applied, and for 3LMP,
no constraints were applied. The grids thus generated were validated for
both the native ligands to check if the RMSD of the docked output was<1
Å from that of the crystal structure. All the prepared ligands were docked
in the two generated grids. Their docking results and binding poses were
analyzed using PyMol (Schr€odinger, LLC). The docking output of ligands
docked in both proteins are summarized in supplementary information,
SI Tables 1 and 2.
4.2. Synthesis of tyramine derivatives
4.2.1. Materials and methods
All the reactions were performed under an atmosphere of argon with
oven-dried glassware. Materials and reagents were obtained from com-
mercial suppliers and used without further purification except when
otherwise noted. All reaction solutions were magnetically stirred with
Teflon stir bars, and temperatures were measured externally. Solvents
were distilled under an argon atmosphere prior to use. Dichloromethane
was dried over P2O5 and triethylamine was distilled over CaH2. Ethanol
and methanol used were reagent-grade solvents. The reaction progress
was monitored on precoated silica gel TLC plates. Spots were visualized
under 254 nm UV light and/or by dipping the TLC plate into a solution of
phosphomolybdic acid staining reagent, followed by heating. Column
chromatography was performed with silica gel (230–400 mesh). 1H and
13C NMR spectra were recorded in MeOD on a 500 MHz Bruker (125
MHz) instrument. Chemical shifts (δ) were reported in parts per million
(ppm) downfield from tetramethylsilane as the internal standard, and
coupling constants are in hertz (Hz). Assignment of proton resonances
was confirmed by correlated spectroscopy. IR spectra were recorded with
a universal attenuated total reflection sampling accessory (diamond
ATR) on an Agilent Cary 630 FT-IR spectrometer.
4.2.1.1. Synthesis of tyramines 8,9, 17-26. General procedure: Substituted
cinnamic acid derivatives (1 equiv.) were dissolved in 2.5 mL of dime-
thylformamide (DMF) and trimethylamine (TEA) (3 equiv., 232 μL). The
solution was cooled in an ice bath and substituted tyramine derivative
(1.25 equiv.) was added followed by the addition of a solution of PyBOP
(1.25 equiv., 362 mg) in dichloromethane (DCM) (2.5 mL). The mixture
was stirred at 0 C for 30 min and then at room temperature for 12 h. The
solvent was removed under reduced pressure and the resulting mixture
was diluted with water (15 mL). The products are extracted with ethyl
acetate (2  15 mL). The combined organic extracts were washed
sequentially with 1N HCl, water, 1M NaHCO3 and brine, dried over
MgSO4, filtered and evaporated. The residue was purified on a silica gel
column (eluent: ethyl acetate: petroleum ether) to obtain compounds 8,
9, 17–26 in 57–83% yield.
4.2.1.2. (E)-3-(3,4-dihydroxyphenyl)-N-(4-hydroxyphenethyl)acrylamide
8 (yield 69%). IR (cm1): 3273, 2492 1649, 1595, 1514, 1463, 1362,
Fig. 6. Blood glucose measurements plotted against time for TEE and compound 9 in (A) vehicle, medium (B, C) and high dosage (D) of the db/db mice (n ¼ 3).
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Fig. 7. a. Metabolic data of the medium-dose groups treated with both drug (9) and extract (TEE): (A) RQ, (B) VO2, (C) VCO2, and (D) heat production (Day –
Daytime; Nigh – Night time).b. Metabolic data of the medium dose groups treated with both drug (9) and extract (TEE) (Day-MA – Daytime motor activity; Nigh-MA –
Night time motor activity).
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1284, 1242, 1114, 975, 850 and 815; 1H NMR (500 MHz, MeOD) δ 7.41
(d, J ¼ 15.6 Hz, 1H), 7.11–7.01 (m, 3H), 6.94–6.88 (m, 1H), 6.79 (d, J ¼
8.1 Hz, 1H), 6.74 (d, J ¼ 8.4 Hz, 2H), 6.36 (d, J ¼ 15.6 Hz, 1H),
3.52–3.47 (t, J¼ 7.3 Hz, 2H), 2.76(t, J¼ 7.3 Hz, 2H); 13C NMR (125MHz,
MeOD) δ 167.9, 155.5, 147.4, 145.3, 140.8, 129.9, 129.4, 126.9, 120.8,
117.0, 115.1, 114.9, 113.7, 41.2, 34.4.
4.2.1.3. (E)-3-(4-hydroxy-3-methoxyphenyl)-N-(4-hydroxyphenethyl)
acrylamide 9 (yield 67%). IR (cm1): 3255, 2492, 1651, 1591, 1514,
1459, 1362, 1279, 1126, 1032, 977 and 819; 1H NMR (500 MHz, MeOD)
δ 7.46 (d, J ¼ 15.6 Hz, 1H), 7.16–7.01 (m, 5H), 6.81 (d, J ¼ 8.1 Hz, 1H),
6.74 (d, J ¼ 8.4 Hz, 2H), 6.42 (d, J ¼ 15.6 Hz, 1H), 3.88 (s, 3H),
3.54–3.45 (m, 2H), 2.77 (t, J¼ 7.3 Hz, 2H); 13C NMR (125MHz, MeOD) δ
167.8, 155.5, 148.4, 147.9, 140.7, 129.9, 129.4, 126.9, 121.9, 117.4,
115.1, 114.9, 110.1, 55.0, 41.2, 34.4 (Supplementary information, SI
Figure C.4 – C.6).
4.2.1.4. (E)-N-(3,4-dihydroxyphenethyl)-3-(3,4-dihydroxyphenyl)acryl-
amide 17 (yield 58%). IR (cm1): 3313, 2939, 2487, 2073, 1648, 1579,
1513, 1463, 1439, 1360, 1280, 1203, 1164, 1122, 973, 850 and 811; 1H
Fig. 8. a. Metabolic data of the high dose groups treated with both 9 and TEE: (F) respiratory quotient, (G) VO2, (H) VCO2, and (I) heat.b. Metabolic data of the high
dose groups treated with both drug (9) and extract (TEE) (Day-MA – Daytime motor activity; Nigh-MA – Night time motor activity).
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Fig. 9. The body composition of the medium-dose group mice treated with drug 9 and TEE: (A) lean mass, (B) fat mass, (C) free water and (D) total water content.
Fig. 10. Heart rate of high-dose group db/db mice treated with a) vehicle, b) drug 9 and c) extract TEE.
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NMR (500 MHz, MeOD) δ 7.40 (d, J ¼ 15.7 Hz, 1H), 7.02 (s, 1H),
6.94–6.89 (m, 1H), 6.78 (d, J¼ 8.1 Hz, 1H), 6.73–6.67 (m, 2H), 6.57 (d, J
¼ 8.0 Hz, 1H), 6.36 (d, J¼ 15.7 Hz, 1H), 3.46 (t, J¼ 7.3 Hz, 2H), 2.71 (t,
J¼ 7.3 Hz, 2H); 13C NMR (125MHz,MeOD) δ 167.9, 147.3, 145.3, 144.9,
143.4, 140.8, 130.7, 126.9, 120.7, 119.7, 117.0, 115.5, 115.0, 113.7,
41.2, 34.7 (Supplementary information, SI Figure C.1 – C.3).
4.2.1.5. (E)-3-(3,4-dihydroxyphenyl)-N-(3-methoxyphenethyl)acrylamide
18 (yield 65%). IR (cm1): 3170, 2944, 2491, 1651, 1585, 1514, 1456,
1362, 1284, 1260, 1203, 1154, 1116, 1039, 978, 851, 814, 783 and 696;
1H NMR (500 MHz, MeOD) δ 7.41 (d, J ¼ 15.6 Hz, 1H), 7.19 (t, J ¼ 8.1
Hz, 1H), 7.03 (s, 1H), 6.91 (d, J ¼ 8.1 Hz, 1H), 6.79 (dt, J ¼ 12.5, 8.0 Hz,
5H), 6.36 (d, J¼ 15.7 Hz, 1H), 3.76 (s, 3H), 3.52 (t, J¼ 7.3 Hz, 2H), 2.83
(t, J ¼ 7.3 Hz, 2H); 13C NMR (125MHz, MeOD) δ 167.9, 159.9, 147.4,
145.3, 140.9, 140.7, 129.1, 126.9, 120.8, 117.0, 115.1, 113.9, 113.5,
111.5, 54.2, 40.8, 35.3.
4.2.1.6. (E)-N-(3,4-dihydroxyphenethyl)-3-(3-methoxyphenyl)acrylamide
19 (yield 57%). IR (cm1): 3245, 2488, 1655, 1598, 1520, 1489, 1456,
1361, 1280, 1256, 1197, 1116, 1047, 977, 850, 784 and 680;1H NMR
(500 MHz, MeOD) δ 7.50 (d, J ¼ 15.7 Hz, 1H), 7.29 (t, J ¼ 7.9 Hz, 1H),
7.13 (d, J¼ 7.6 Hz, 1H), 7.09 (s, 1H), 6.94 (dd, J¼ 8.1, 2.1 Hz, 1H), 6.71
(dd, J¼ 9.7, 4.9 Hz, 2H), 6.58 (dd, J¼ 8.7, 7.0 Hz, 2H), 3.81 (s, 3H), 3.48
(t, J¼ 7.3 Hz, 2H), 2.72 (t, J¼ 7.3 Hz, 2H); 13C NMR (125MHz, MeOD) δ
167.2, 160.1, 144.9, 143.4, 140.2, 136.3, 130.7, 129.5, 120.8, 120.0,
119.7, 115.5, 115.1, 112.4, 54.3, 41.2, 34.6.
4.2.1.7. (E)-N-(4-hydroxyphenethyl)-3-(3-methoxyphenyl)acrylamide 20
(yield 83%). IR (cm1): 2967, 2868, 2396, 1656, 1610, 1516, 1489,
1453, 1361, 1242, 1206, 1156, 1087, 1048, 1015, 982, 831, 782 and
681; 1H NMR (500 MHz, MeOD) δ 7.50 (d, J ¼ 15.7 Hz, 1H), 7.30 (t, J ¼
7.9 Hz, 1H), 7.13 (d, J ¼ 7.6 Hz, 1H), 7.11–7.05 (m, 4H), 6.94 (dd, J ¼
8.1, 2.0 Hz, 1H), 6.74 (d, J ¼ 8.3 Hz, 2H), 6.59 (d, J ¼ 15.8 Hz, 1H), 3.82
(s, 4H), 3.49 (t, J ¼ 7.4 Hz, 2H), 2.78 (t, J ¼ 7.3 Hz, 2H); 13C NMR
(125MHz, MeOD) δ 167.1, 160.1, 155.6, 140.2, 136.3, 129.8, 129.6,
129.4, 120.8, 120.0, 115.1, 114.9, 112.4, 54.4, 41.2, 34.4.
4.2.1.8. (E)-N-(4-hydroxyphenethyl)-3-(3-methoxyphenyl)acrylamide 21
(yield 82%). IR (cm1): 3277, 3070, 2935, 2835, 1655, 1602, 1582,
1546, 1488, 1454, 1433, 1367, 1315, 1209, 1217, 1153, 1039, 979, 849,
779, 695 and 677; 1H NMR (500MHz, CDCl3) δ 7.60 (d, J¼ 15.5 Hz, 1H),
7.27 (dt, J¼ 11.3, 7.8 Hz, 3H), 7.09 (d, J¼ 7.6 Hz, 1H), 7.02 (s, 1H), 6.91
(d, J ¼ 8.1 Hz, 1H), 6.82 (dd, J ¼ 14.7, 9.4 Hz, 3H), 6.35 (d, J ¼ 15.6 Hz,
1H), 5.83 (bs, 1H), 3.83 (s, 3H), 3.81 (s, 3H), 3.68 (m, 2H), 2.89 (t, J ¼
6.8 Hz, 2H); 13C NMR (125MHz, CDCl3) δ 165.9, 159.9, 140.9, 140.5,
136.2, 129.8, 121.06, 120.4, 115.4, 114.5, 112.9, 111.9, 55.3, 40.7, 35.7.
4.2.1.9. (E)-N-(3,4-dihydroxyphenethyl)-3-(4-hydroxy-3-methoxyphenyl)
acrylamide 22 (yield 65%). IR (cm1): 3322, 2492, 1651, 1591, 1515,
1461, 1362, 1280, 1205, 1123, 1032, 976, 845 and 815; 1H NMR (500
MHz, MeOD) δ 7.46 (d, J ¼ 15.7 Hz, 1H), 7.12 (s, 1H), 7.03 (dd, J ¼ 8.1,
1.4 Hz, 1H), 6.81 (d, J ¼ 8.1 Hz, 1H), 6.71 (dd, J ¼ 9.4, 4.8 Hz, 2H), 6.57
(dd, J¼ 7.8, 1.5 Hz, 1H), 6.43 (d, J¼ 15.7 Hz, 1H), 3.89 (s, 3H), 3.48 (t, J
¼ 7.3 Hz, 2H), 2.72 (t, J ¼ 7.2 Hz, 2H); 13C NMR (125MHz, MeOD) δ
167.8, 148.4, 147.9, 144.9, 143.4, 140.6, 130.7, 126.9, 121.8, 119.7,
117.4, 115.5, 115.1, 110.1, 55.0, 41.2, 34.7.
4.2.1.10. (E)-3-(4-hydroxy-3-methoxyphenyl)-N-(3-methoxyphenethyl)
acrylamide 23 (yield 75%). IR (cm1): 2938, 2482, 1652, 1600, 1585,
1514, 1456, 1434, 1362, 1281, 1262, 1281, 1262, 1206, 1157, 1125,
1035, 979, 846, 818, 782 and 696; 1H NMR (500 MHz, MeOD) δ 7.46 (d,
J ¼ 15.7 Hz, 1H), 7.21 (t, J ¼ 8.0 Hz, 1H), 7.12 (s, 1H), 7.04 (dd, J ¼ 8.1,
1.3 Hz, 1H), 6.82 (t, J¼ 7.8 Hz, 2H), 6.80–6.75 (m, 1H), 6.42 (d, J¼ 15.6
Hz, 1H), 3.89 (s, 3H), 3.78 (s, 3H), 3.54 (t, J ¼ 7.3 Hz, 2H), 2.85 (t, J ¼
Fig. 11. Blood pressure of high-dose group db/db mice treated with a) vehicle b) drug 9 and c) extract TEE.
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7.2 Hz, 2H); 13C NMR (125MHz, MeOD) δ 167.8, 159.9, 148.5, 147.9,
140.7, 129.1, 126.8, 121.8, 120.7, 117.3, 115.1, 114.0, 111.5, 110.1,
55.0, 54.2, 40.8, 35.3.
4.2.1.11. (E)-N-(3,4-dihydroxyphenethyl)-3-(4-hydroxy-3,5-dimethox-
yphenyl)acrylamide 24 (yield 71%). IR (cm1): 3339, 2939, 2492, 2071,
1652, 1603, 1514, 1457, 1427, 1337, 1282, 1216, 1156, 1114, 975, 869
and 827; 1H NMR (500 MHz, MeOD) δ 7.43 (d, J ¼ 15.6 Hz, 1H), 6.82 (s,
2H), 6.75–6.69 (m, 2H), 6.57 (d, J ¼ 7.9 Hz, 1H), 6.45 (d, J ¼ 15.6 Hz,
1H), 3.85 (s, 7H), 3.50 (t, J ¼ 7.2 Hz, 2H), 2.72 (t, J ¼ 7.2 Hz, 2H); 13C
NMR (125MHz, MeOD) δ 167.7, 148.0, 144.9, 143.4, 140.9, 137.4,
130.7, 125.9, 119.8, 117.9, 115.6, 115.1, 105.0, 55.4, 41.2, 34.6 (Sup-
plementary information, SI Figure C.7 – C.9).
4.2.1.12. (E)-3-(4-hydroxy-3,5-dimethoxyphenyl)-N-(4-hydroxyphenethyl)
acrylamide 25 (yield 69%). IR (cm1): 3339, 2939, 2493, 2071, 1652,
1603, 1514, 1457, 1427, 1337, 1282, 1216, 1156, 1114, 975, 868 and
827; 1H NMR (500 MHz, MeOD) δ 7.44 (d, J ¼ 15.6 Hz, 1H), 7.06 (d, J ¼
8.2 Hz, 2H), 6.83 (s, 2H), 6.74 (d, J ¼ 8.2 Hz, 2H), 6.45 (d, J ¼ 15.6 Hz,
1H), 3.86 (s, 6H), 3.49 (t, J ¼ 7.3 Hz, 2H), 2.77 (t, J ¼ 7.2 Hz, 2H); 13C
NMR (125MHz, MeOD) δ 167.7, 155.57, 148.0, 140.9, 137.5, 129.9,
129.4, 125.8, 117.8, 114.9, 105.0, 55.4, 41.2, 34.4.
4.2.1.13. (E)-3-(4-hydroxy-3,5-dimethoxyphenyl)-N-(3-methox-
yphenethyl)acrylamide 26 (yield 72%). IR (cm1): 3282, 2938, 2839,
2252, 1655, 1602, 1513, 1490, 1455, 1425, 1320, 1285, 1259, 1209,
1153, 1112, 1061, 1038, 976, 907, 828, 780 and 696; 1H NMR (500
MHz, MeOH) δ 7.52 (d, J ¼ 15.5 Hz, 1H), 7.22 (t, J ¼ 7.9 Hz, 1H), 6.79
(dd, J¼ 16.6, 6.9 Hz, 3H), 6.70 (s, 2H), 6.27 (d, J¼ 15.5 Hz, 1H), 6.09 (s,
1H), 6.02 (s, 1H), 3.84 (s, 6H), 3.77 (s, 3H), 3.69–3.61 (m, 2H), 2.86 (t, J
¼ 6.7 Hz, 2H); 13C NMR (125MHz, MeOH) δ 166.2, 159.8, 147.2, 141.1,
140.6, 136.6, 129.6, 126.3, 121.1, 118.7, 114.5, 111.8, 104.8, 56.3, 55.2,
40.7, 35.7.
4.2.2. Synthesis of compounds 6, 27–37
General Procedure: The unsaturated tyramine derivatives (8, 9, 17–26)
(0.150 mmol) were dissolved in methanol (1.5 mL) and to this solution,
palladium on carbon 5% (0.010 g, 0.0944 mmol) was added and purged
with hydrogen gas. The resulting mixture was stirred for 12 h at room
temperature under hydrogen atmosphere (with H2 filled balloon). After
12 h, the reactionmixture was filtered over Celite, washedwithmethanol
(2  10 mL) and the combined washings were concentrated and purified
by flash column chromatography using chloroform and methanol (94:6)
to yield the saturated amide derivatives (6, 27–37) in 49–90% yield.
4.2.2.1. 3-(3,4-Dihydroxyphenyl)-N-(4-hydroxyphenethyl)propanamide 6
(yield 68%). IR (cm1): 3282, 2499, 1610, 1515, 1449, 1361, 1284,
1242, 1115, 976 and 819; 1H NMR (500 MHz, MeOD) δ 6.97 (d, J ¼ 8.3
Hz, 2H), 6.69 (dd, J ¼ 20.7, 11.9 Hz, 4H), 6.53 (d, J ¼ 6.5 Hz, 1H), 3.32
(dd, J ¼ 12.7, 5.1 Hz, 2H), 2.75 (t, J ¼ 7.5 Hz, 2H), 2.63 (t, J ¼ 7.3 Hz,
2H), 2.39 (t, J ¼ 7.6 Hz, 2H); 13C NMR (125MHz, MeOD) δ 174.0, 155.4,
144.8, 132.4, 129.9, 129.3, 119.2, 115.2, 115.0, 114.8, 40.9, 38.0, 34.3,
31.1.
4.2.2.2. N-(3,4-dihydroxyphenethyl)-3-(3,4-dihydroxyphenyl)propanamide
27 (yield 49%). IR (cm1):3314, 2935, 2501, 2073, 1599, 1517, 1481,
1440, 1359, 1282, 1199, 1152, 1115, 972, 870, 811 and 783; 1H NMR
(500 MHz, MeOD) δ 6.69 (dd, J ¼ 8.0, 1.2 Hz, 2H), 6.65 (dd, J ¼ 5.7, 1.6
Hz, 2H), 6.52 (dd, J ¼ 8.0, 1.6 Hz, 1H), 6.48 (dd, J ¼ 7.9, 1.6 Hz, 1H),
3.33–3.27 (m, 2H), 2.75 (t, J¼ 7.6 Hz, 2H), 2.57 (t, J¼ 7.7 Hz, 2H), 2.39
(t, J ¼ 7.7 Hz, 2H); 13C NMR (125MHz, MeOD) δ 174.1, 144.8, 143.3,
132.4, 130.7, 119.7, 119.2, 115.5, 115.2, 114.9, 114.9, 40.9, 38.1, 34.6,
31.1.
4.2.2.3. 3-(3,4-dihydroxyphenyl)-N-(3-methoxyphenethyl)propanamide 28
(yield 62%). IR (cm1): 3276, 2938, 2491, 1595, 1515, 1453, 1437,
1360, 1282, 1201, 1166, 1152, 1116, 1061, 1038, 869, 812, 781, 743
and 696; 1H NMR (500MHz, MeOD) δ 7.18 (t, J¼ 8.0 Hz, 1H), 6.71 (ddd,
J ¼ 21.9, 13.9, 4.1 Hz, 5H), 6.55–6.48 (m, 1H), 3.76 (s, 3H), 3.40–3.32
(m, 3H), 2.72 (dt, J¼ 20.7, 7.3 Hz, 4H), 2.39 (t, J¼ 7.6 Hz, 2H); 13C NMR
(125MHz, MeOD) δ 174.1, 159.9, 144.8, 143.2, 140.7, 132.4, 129.1,
120.8, 119.2, 115.2, 114.9, 113.9, 111.5, 54.2, 40.5, 38.1, 35.2, 31.1.
4.2.2.4. N-(3,4-dihydroxyphenethyl)-3-(3-methoxyphenyl)propanamide 29
(yield 69%). IR (cm1): 3280, 2939,2507, 1627, 1602, 1519, 1485,
1465, 1455, 1440, 1359, 1278, 1260, 1197, 1152, 1116, 1049, 872, 784
and 697; 1H NMR (500MHz, MeOD) δ 7.18 (t, J¼ 8.0 Hz, 1H), 6.81–6.73
(m, 3H), 6.69 (d, J ¼ 8.0 Hz, 1H), 6.64 (d, J ¼ 1.4 Hz, 1H), 6.47 (d, J ¼
6.4 Hz, 1H), 3.78 (s, 3H), 3.32 (t, J¼ 7.6 Hz, 2H), 2.87 (t, J¼ 7.6 Hz, 2H),
2.58 (t, J ¼ 7.3 Hz, 2H), 2.45 (t, J ¼ 7.3 Hz, 2H); 13C NMR (125MHz,
MeOD) δ 173.8, 159.9, 144.9, 143.4, 142.4, 130.7, 129.0, 120.3, 119.7,
115.4, 114.9, 113.7, 111.3, 54.2, 40.9, 37.5, 34.5, 31.6.
4.2.2.5. N-(4-hydroxyphenethyl)-3-(3-methoxyphenyl)propanamide 30
(yield 91%). IR (cm1): 2947, 2868, 1635, 1614, 1516, 1455, 1362,
1261, 1261, 1207, 1153, 1087, 1015, 831, 780 and 697; 1H NMR (500
MHz, MeOD) δ 7.18 (t, J ¼ 8.0 Hz, 1H), 6.96 (d, J ¼ 8.3 Hz, 2H),
6.82–6.74 (m, 3H), 6.71 (d, J ¼ 8.4 Hz, 2H), 3.77 (s, 3H), 3.35–3.29 (m,
2H), 2.87 (t, J ¼ 7.6 Hz, 2H), 2.62 (t, J ¼ 7.6 Hz, 2H), 2.45 (t, J ¼ 7.6 Hz,
2H); 13C NMR (125MHz, MeOD) δ 173.7, 159.9, 155.5, 142.4, 129.9,
129.3, 129.1, 120.4, 114.9, 113.7, 111.3, 54.2, 40.9, 37.5, 34.3, 31.6.
4.2.2.6. N-(3-methoxyphenethyl)-3-(3-methoxyphenyl)propanamide 31
(yield 77%). IR (cm1): 3294, 2937, 1644, 1602, 1585, 1547, 1490,
1455, 1260, 1152, 1041, 874, 780 and 696; 1H NMR (500MHz, MeOD) δ
7.18 (dd, J ¼ 10.6, 5.4 Hz, 2H), 6.82–6.72 (m, 6H), 3.78 (s, 6H),
3.40–3.35 (m, 2H), 2.87 (t, J ¼ 7.7 Hz, 2H), 2.71 (t, J ¼ 7.3 Hz, 2H),
2.46–2.42 (t, J¼ 7.3 Hz, 2H); 13C NMR (125MHz, MeOD) δ 173.8, 159.9,
142.3, 140.6, 129.0, 120.7, 120.3, 113.9, 113.8, 111.4, 111.2, 54.2, 40.5,
37.5, 35.2, 31.6.
4.2.2.7. N-(3,4-dihydroxyphenethyl)-3-(4-hydroxy-3-methoxyphenyl)prop-
anamide 32 (yield 59%). IR (cm1): 3338, 2938, 2500, 1600, 1516,
1465, 1449, 1362, 1275, 1153, 1123, 1034, 976, 870 and 814; 1H NMR
(500 MHz, MeOD) δ 6.78 (d, J ¼ 1.7 Hz, 1H), 6.72 (d, J ¼ 8.0 Hz, 1H),
6.69 (d, J¼ 8.0 Hz, 1H), 6.63 (dd, J¼ 5.8, 1.9 Hz, 2H), 6.46 (dd, J¼ 8.0,
1.9 Hz, 1H), 3.83 (s, 3H), 3.30 (d, J ¼ 7.6 Hz, 2H), 2.81 (t, J ¼ 7.6 Hz,
2H), 2.58 (t, J¼ 7.7 Hz, 2H), 2.42 (t, J¼ 7.7 Hz, 2H); 13C NMR (125MHz,
MeOD) δ 174.1, 147.5, 144.9, 144.5, 143.4, 132.4, 130.7, 120.4, 119.7,
115.4, 114.9, 114.8, 111.7, 54.9, 40.9, 38.0, 34.6, 31.3.
4.2.2.8. 3-(4-Hydroxy-3-methoxyphenyl)-N-(4-hydroxyphenethyl)prop-
anamide 33 (yield 88%). IR (cm1): 3279, 2938, 2499, 1627, 1613,
1596, 1515, 1465, 1452, 1436, 1363, 1236, 1153, 1125, 1034 and 822;
1H NMR (500MHz, MeOD) δ 6.95 (d, J¼ 8.4 Hz, 2H), 6.78 (d, J¼ 1.7 Hz,
1H), 6.74–6.69 (m, 3H), 6.64 (dd, J ¼ 8.0, 1.7 Hz, 1H), 3.84 (s, 3H),
3.33–3.28 (m, 2H), 2.81 (t, J¼ 7.5 Hz, 2H), 2.62 (t, J¼ 7.3 Hz, 2H), 2.42
(t, J¼ 7.5 Hz, 2H); 13C NMR (125MHz, MeOD) δ 173.97, 155.47, 147.48,
144.50, 132.33, 129.88, 129.3, 120.4, 114.8, 114.8, 111.8, 54.9, 40.9,
37.9, 34.3, 31.2.
4.2.2.9. 3-(4-Hydroxy-3-methoxyphenyl)-N-(3-methoxyphenethyl)prop-
anamide 34 (yield 90%). IR (cm1): 2937, 2488, 1631, 1600, 1516,
1465, 1433, 1363, 1260, 1153, 1125, 1037, 854, 787 and 697; 1H NMR
(500 MHz, MeOD) δ 7.17 (dd, J ¼ 8.8, 7.6 Hz, 1H), 6.81–6.74 (m, 3H),
6.72 (d, J¼ 7.9 Hz, 2H), 6.63 (dd, J¼ 8.0, 1.8 Hz, 1H), 3.83 (s, 4H), 3.78
(d, J¼ 7.9 Hz, 3H), 3.37 (t, J¼ 7.3 Hz, 2H), 2.81 (t, J¼ 7.6 Hz, 2H), 2.70
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(t, J¼ 7.3 Hz, 2H), 2.42 (t, J¼ 7.6 Hz, 2H); 13C NMR (125MHz, MeOD) δ
174.0, 159.9, 147.5, 144.5, 140.6, 132.3, 129.1, 120.7, 120.4, 114.8,
113.9, 111.7, 111.4, 54.9, 54.2, 40.5, 37.9, 35.2, 31.2.
4.2.2.10. N-(3,4-dihydroxyphenethyl)-3-(4-hydroxy-3,5-dimethoxyphenyl)
propanamide 35 (yield 87%). IR (cm1): 3348, 2939, 2499, 1611, 1519,
1461, 1345, 1282, 1215, 1114, 977 and 814; 1H NMR (500 MHz, MeOD)
δ 6.68 (d, J ¼ 8.0 Hz, 1H), 6.63 (d, J ¼ 1.9 Hz, 1H), 6.52–6.47 (m, 2H),
6.45 (dd, J ¼ 8.0, 1.9 Hz, 1H), 3.82 (s, 6H), 3.33–3.29 (m, 2H), 2.82 (t, J
¼ 7.5 Hz, 2H), 2.75 (t, J¼ 7.6 Hz, 2H), 2.43 (t, J¼ 7.6 Hz, 2H); 13C NMR
(125MHz, MeOD) δ 173.9, 147.8, 144.9, 143.3, 133.5, 131.6, 130.6,
119.7, 115.4, 114.9, 105.3, 55.3, 40.9, 37.9, 34.6, 31.7.
4.2.2.11. 3-(4-Hydroxy-3,5-dimethoxyphenyl)-N-(4-hydroxyphenethyl)
propanamide 36 (yield 90%). IR (cm1): 2941, 2506, 2189, 2028, 1621,
1603, 1512, 1486, 1456, 1437, 1351, 1328, 1260, 1242, 1139, 1050,
969, 837 and 757; 1H NMR (500 MHz, MeOD) δ 6.94 (d, J¼ 8.4 Hz, 2H),
6.70 (d, J ¼ 8.4 Hz, 2H), 6.48 (s, 2H), 3.83 (s, 7H), 3.36–3.30 (m, 4H),
2.82 (t, J ¼ 7.5 Hz, 2H), 2.62 (t, J¼ 7.3 Hz, 2H), 2.43 (t, J¼ 7.5 Hz, 2H);
13C NMR (125MHz, MeOD) δ 173.9, 155.4, 147.8, 133.5, 131.6, 129.9,
129.4, 114.9, 105.3, 55.5, 40.9, 38.1, 34.4, 31.8.
4.2.2.12. 3-(4-Hydroxy-3,5-dimethoxyphenyl)-N-(3-methoxyphenethyl)
propanamide 37 (yield 89%). IR (cm1): 3299, 2938, 2838, 2496, 1633,
1603, 1518, 1458, 1429, 1326, 1259, 1213, 1152, 1114, 1040, 908, 830,
785 and 697; 1H NMR (500 MHz, MeOD) δ 7.21–7.14 (m, 1H), 6.75 (d, J
¼ 6.0 Hz, 2H), 6.70 (d, J¼ 7.5 Hz, 1H), 6.49 (s, 2H), 3.82 (s, 7H), 3.77 (s,
3H), 3.37 (t, J ¼ 7.3 Hz, 2H), 2.82 (t, J ¼ 7.5 Hz, 2H), 2.70 (t, J ¼ 7.3 Hz,
2H), 2.43 (t, J ¼ 7.5 Hz, 2H); 13C NMR (125MHz, MeOD) δ 173.9, 159.9,
147.8, 140.6, 133.6, 131.6, 129.1, 120.7, 113.9, 111.4, 105.3, 55.3, 54.2,
40.5, 37.9, 35.2, 31.7.
4.3. Preparation of the tyramine-enriched extract (TEE) of L. chinense
The root bark of L. chinense (2 kg) was extracted with methanol (8 L)
at room temperature to get the crude extract (345.5 g). This methanolic
extract was suspended in water and successively partitioned between
hexanes and ethyl acetate and 35.1 grams of crude material was obtained
from the ethyl acetate extract. The crude material (33 g) was dissolved in
ethyl acetate (300 mL) and washed with 5% HCl in water (approx. 1 L)
and the aqueous layer was further extracted with ethylactate (2  300
mL) to yield crude material (20.6 g). This ethyl acetate fraction (18.0 g)
was subjected to Sephadex LH-20 column chromatography with
CHCl3:MeOH (1:1) as a solvent to get three fractions (1–3), LC-MS
analysis indicated tyramine compounds are in fraction 3 (6.49 g)
which was further chromatographed over Sephadex LH-20 column
chromatography with MeOH to get three sub-fractions. Analysis of the
third sub-fraction by comparative TLC using a pure tyramine 9 indicated
that it is a tyramine enriched fraction, TEE. The calculated concentration
of the tyramines in TEE is 21% based on the reported isolation yields
[37].
4.4. In vitro testing
Ciprofibrate and rosiglitazone 1, were obtained from Cayman
Chemical (Ann Arbor, MI). Dulbecco's Modified Eagle's Medium
(DMEM), fetal bovine serum (FBS) and phosphate-buffered saline (PBS)
were purchased from Hyclone (South Logan, Utah). Penicillin/strepto-
mycin and trypsin were procured from Gibco (Grand Island, NY). Specific
plasmids pSG5–PPARα (plasmid 22751) and PPRE X3-tk-luc (plasmid
1015) were obtained from Addgene (Cambridge, MA). pCMV-rPPARγ
and pPPREaP2-tk-luc were provided by Dr. Dennis Feller (Department of
Pharmacology, University of Mississippi).
4.4.1. Reporter gene assay for the activation of PPARs
Cell-based reporter gene assay for the identification of PPARα and
PPARγ agonists was carried out in human hepatoma (HepG2) cells as
described previously [41, 44]. Briefly, HepG2 cells were cultured in
Dulbecco's Modified Eagle's Medium (DMEM), supplemented with 10%
fetal bovine serum (FBS), 100 units/mL penicillin, and 100 μg/mL
streptomycin in a humidified atmosphere of 5% CO2 at 37 C. HepG2
cells were transfected with either pSG5-PPARα and PRE X3-tk-luc or
pCMV-rPPARγ and pPPREaP2-tk-luc plasmid DNA (25 μg of each/1.5 mL
cell suspension) by electroporation at 160 V for a single 70ms pulse using
a BTX Electro Square Porator T820 (BTX, San Diego, CA). Transfected
cells were plated at a density of 5  104 cells/well in 96-well tissue
culture plates and grown for 24 h. The cells were treated with various
concentrations of the test samples, ciprofibrate or rosiglitazone 1 (30
μM). After incubation for 24 h, the cells were lysed and the luciferase
activity was measured using a luciferase assay system (Promega, Madi-
son, WI). The fold activation of luciferase activity in sample-treated cells
was calculated in comparison to the vehicle-treated cells.
4.5. In vivo testing
The experimental procedures and protocols for these studies followed
the National Institutes of Health Guide for the Care and Use of Laboratory
Animals and were approved by the Institutional Animal Care and Use
Committee of the University of Mississippi Medical Center.
4.5.1. Animals
Male diabetic db/db mice from the Jackson Laboratories (Ann Arbor,
MI, USA) at 12 weeks of age were used in these studies. The mice were
divided into medium- (n ¼ 6) and high-dose groups (n ¼ 8). In the me-
dium-dose group, mice were treated with 16 mg/kg of TEE (n ¼ 3) or 8
mg/kg of 9. In the high-dose group (n ¼ 8), mice were treated with
vehicle (n ¼ 3), 32 mg/kg of 9 (n ¼ 3, out of which 1 mouse died during
treatment) or 64 mg/kg of extract TEE. The animals were followed for
one to two weeks control period before treatment was started. In the
medium-dose groups, EchoMRIs were performed during control and
experimental periods. High-dose group mice were implanted with
transmitters to record the blood pressure and heart rate 24-hr/day for 3
consecutive days. Animals were dosed by gavage.
4.5.2. Body weight and body composition analysis
Male db/db mice were individually housed and fed standard chow
(Harlan Teklad, WI). Body weight and food intakes were measured
weekly, starting at 12 weeks through 16 weeks of age in order to examine
the role of Lycium Chinense in regulating body weight. Body composition
measurements were performed using magnetic resonance imaging
(EchoMRI-900TM, Echo Medical System, Houston, TX) to quantify lean
mass, fat mass, and free water and total water content in conscious mice.
4.5.3. Glucose tolerance test
D-glucose (3 mg/g of lean tissue plus 1 mg/g of fat mass) was
administered by gavage after a 6-hour fast in 12, 14 and 15-week-old
male db/db mice (n ¼ 9). Blood samples were collected by tail snip
and blood glucose was measured at 0, 15, 30, 60, 90 and 120 min after
glucose injection using glucose strips (ReliOn™).
4.5.4. Telemetry probe implantation
Male db/db mice were anesthetized with 2% isoflurane and, under
sterile conditions, a telemetry probe (TA11PA-C10, Data Science, MN)
was implanted in the left carotid artery for determination of mean arte-
rial pressure (MAP) and heart rate (HR) 24 hours per day using
computerized methods for data collection as previously described [45,
46]. MAP and HR were obtained from the average of 24 h of recording
C. Yalamanchili et al. Heliyon 6 (2020) e02782
14
using a sampling rate of 1000 Hz with a duration of 10 s every 10-minute
period.
4.5.5. Experimental design for Telemetry probe implantation
4.5.5.1. Chronic 9 and TEE (Lycium Chinense) treatment. After 6–16 days
of baseline measurements, the mice were randomly assigned to one of
three groups and maintained for the remaining 18 days of the study: TEE
(n ¼ 3), mice were dosed by daily oral gavage (0.3 ml); 2) drug treated-
high dose (n ¼ 3), mice were dosed by daily 32 mg/kg; and 3) drug
treated-medium-dose (n ¼ 3), mice were dosed by daily 8 mg/kg. After
an 8–10 day post-surgery recovery period and 5 days of stable baseline
control measurements, TEE or drug was given at the high-dose by gavage
for 18 days. MAP and HR were recorded daily. In addition, the glucose
tolerance test was performed during baseline control and repeated at the
end of one and two weeks of treatment.
4.5.5.2. Oxygen consumption and motor activity. In separate experiments,
db/db mice were placed individually in metabolic cages (AccuScan In-
struments Inc, Columbus, OH) equipped with oxygen sensors to measure
oxygen consumption (VO2) and infrared beams to determine motor ac-
tivity. VO2 was measured for 2 min at 10-minute intervals continuously,
24-hours a day using a Zirconia oxygen sensor. Motor activity in X, Y and
Z axes was determined using infrared light beams mounted in the cages.
After the mice were acclimatized to the new environment for approxi-
mately 4–6 days, VO2 and animal activity were recorded for 3 consecu-
tive days. Then the mice were administered by gavage, TEE, high- and
medium-doses of L. Chinense for 18 days and then placed in metabolic
cages during the last 4 days of treatment.
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